insulin lispro (humalog) Report issue

Biologics Recombinant protein Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is delivered subcutaneously either by injection or from an insulin pump. Onset of effects typically occurs within 30 minutes and lasts about 5 hours. Often a longer-acting insulin like insulin NPH is also needed.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$5.2033 - $187.6400

Australia

$17.5063 - $60.4036
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( insulin human (humulin), insulin lispro (humalog) - other names: humalog mix 50/50 kwikpen, humalog mix 50/50 pen, humalog mix 75/25 kwikpen, humalog mix 75/25 pen, novolog mix, novolog mix 70/30 flexpen, novolog mix 70/30 penfill )
|
( insulin degludec (tresiba), insulin lispro (humalog) )

Alternative names

29866 | aspart | aspart insulin | b28-aspart-insulin | b28-asp-insulin | biasp30 | biasp 30 | biod-123 | biphasic insulin aspart 30 | biphasic insulin aspart 30:70 | humalog | humalog kwikpen | humalog lispro | humalog pen | ina-x14 | ins humalog | ins novorapid | insulin apart | insulin aspart | insulin aspart protamine | insulin aspart protamine crystalline | insulin aspart protamine recombinant | insulin aspart recombinant | insulin, asp(b28) | insulin lispro | insulin lispro (genetical recombination) | insulin,lispro,human/rdna | insulin lispro protamine | insulin,lispro,protamine/rdna | insulin lispro protamine recombinant | insulin lispro (rdna origin) | insulin lispro recombinant | insulin peglispro | insulin x14 | levopropoxyphene napsylate | levopropoxyphene napsylate anhydrous | liprolog | lispro insulin | ly2605541 | ly900014 | novolog | novolog flexpen | novolog innolet | novolog mix 70:30 | novolog penfill | novomix | novomix 30 | novorapid | novrad

Organizations (180)

Research & Development (178)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (39)

Approved Indications (2)


 

Diabetes, Gestational

Diabetes Mellitus

Experimental Indications - Clinical Trial Phases 1-4 (39)


 

Alzheimer Disease (Phase 1/Phase 2)

Arteriosclerosis (Phase 4)

Asthma (Phase 3)

Atherosclerosis (Phase 4)

Cardiovascular Diseases (Phase 3)

Cognition Disorders (Phase 2)

Cognitive Dysfunction (Phase 1)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 3)

Critical Illness (Phase 4)

Cystic Fibrosis (Phase 3)

Delivery, Obstetric (Phase 1)

Diabetes, Gestational (Phase 4)

Diabetes Mellitus ()

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 4)

Diabetic Retinopathy (Early Phase 1)

Diet Therapy (Phase 2)

Endocrine System Diseases (Phase 2)

Fibrosis (Phase 4)

General Surgery (Phase 2)

Glucose Metabolism Disorders (Phase 2)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Hospitalization (Phase 4)

Hypercholesterolemia (Phase 3)

Hyperglycemia (Phase 4)

Hypertension (Phase 3)

Hypoglycemia (Phase 4)

Inflammation (Phase 2)

Leukemia (Phase 3)

Lymphoma (Phase 3)

Metabolic Diseases (Phase 2)

Myocardial Infarction (Phase 4)

Pharmacological and Toxicological Phenomena (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Ventricular Dysfunction (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 558
  • # of Trial Organizations: 178

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue